A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

Trial Details

NCT ID
NCT05877599
Phase
PHASE1
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Autologous, engineered T Cells targeting TP53 R175H
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Duarte, California, United States|34.13945,-117.97729
  • Newport Beach, California, United States|33.61891,-117.92895
  • Santa Monica, California, United States|34.01949,-118.49138
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Subjects must be at least 18 years of age, at the time of signing the informed consent.
  • Subjects must be capable of giving signed informed consent.
  • Subject must be diagnosed with one of the histologies below:
  • Colorectal adenocarcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →